Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
Misato TsubokuraYuko AdegawaMinoru KojimaRyuji TanosakiRyuzaburo OhtakeYuki KaseNao IwashitaMoemi KasaneSaori NakabayashiSayaka TakeuchiKen KatoNarikazu BokuYukihide KanemitsuTakuji OkusakaHiroyuki FujimotoKan YonemoriHiroto IshikiKimihiko KawamuraEriko SatomiHiromichi MatsushitaPublished in: BMC cancer (2022)
The observed AEs were mainly mild reactions after reinfusion, which were related to a reinfusion rate of volume ≥ 125 mL/h, a simple indicator in practice, or total protein ≥ 10.9 g/h. Although our study was retrospective in nature and undertaken in a single institute, this information may be helpful for the management of cancer patients with refractory malignant ascites using CART.